| Identification | Back Directory | [Name]
ORITAVANCIN | [CAS]
171099-57-3 | [Synonyms]
CS-2274
Orbactiv
LY 333328
ORITAVANCIN
171099-57-3
brand name: Orbactiv
Oritavancin (LY333328)
Oritavancin, trifluoacetate salt
Oritavancin (Lyophilized Powder For IV Infusion)
rideoxy-3-methyl-α-L-arabino-hexopyranosyl)-β-D-g
LY333328; LY-333328; LY 333328; ORITAVANCIN; BRAND NAME: ORBACTIV
(4R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(p-chlorophenyl)benzyl)vancomycin
(4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]vancomycin
Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-arabino-hexopyranosyl)-N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-, (4''R)-
(1S,2R,18R,19R,22S,25R,28R,40R)-22-(2-Amino-2-oxoethyl)-2-[(3-amino-2,3,6-trideoxy-3-methyl-α-L-arabino-hexopyranosyl)oxy]-5,15-dichloro-48-{[2-O-(3-{[(4'-chloro-4-biphenylyl)methyl]amino}-2,3,6-t
| [Molecular Formula]
C86H97Cl3N10O26 | [MDL Number]
MFCD09837768 | [MOL File]
171099-57-3.mol | [Molecular Weight]
1793.12 |
| Hazard Information | Back Directory | [Definition]
ChEBI: A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA. | [Clinical Use]
Antibacterial agent | [Enzyme inhibitor]
This novel, semi-synthetic glycopeptide antibiotic (FW = 1793.10 g/mol;
CAS 171099-57-3), also known as LY333328, Orbactiv®, and (4R) -22-O-
3
(3-amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl) -N- (p- (p-
chlorophenyl) benzyl) vancomycin, disrupts the cell membrane of Gram-
positive bacteria and inhibits both transglycosylation and
transpeptidation. Oritavancin differs from vancomycin by the presence
of a hydrophobic N-4- (4-chlorophenyl) benzyl substituent on the
disaccharide, the addition of a 4-epi-vancosamine monosaccharide to the
amino acid residue in Ring-6, and replacement of the vancosamine moiety
by 4-epi-vancosamine. When compared vancomycin, teicoplanin, and
quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and
staphylococci, including vancomycin-resistant enterococci and methicillin-
resistant Staphylococcus aureus, LY333328 demonstrated superior activity
against vancomycin-resistant enterococci and was the only antibiotic which
was bactericidal. Indeed, a single infusion of this antibiotic (1200 mg) can
clear serious bacterial skin infections, including methicillin-resistant
Staphylococcus aureus, or MRSA, as effectively as the usual 7-10 day,
twice-daily regimen of vancomycin now needed to treat patients. | [Drug interactions]
Potentially hazardous interactions with other drugs
Anticoagulants: possibly increases warfarin
concentration. | [Metabolism]
In vitro human liver microsome studies indicated that
oritavancin is not metabolised. It is excreted unchanged;
less than 1% and 5% of a dose is recovered in the urine
and the faeces. |
|
|